Analyst Price Targets — SNTI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 21, 2025 1:27 pm | Jeffrey La Rosa | Leerink Partners | $6.00 | $1.82 | TheFly | Senti Bio initiated with an Outperform at Leerink |
Latest News for SNTI
Senti Biosciences (NASDAQ: SNTI - Get Free Report) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.33) per share and revenue of $0.0150 million for the quarter. Individuals are encouraged to explore the company's upcoming Q2 2026 earning summary page
SOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) (“SBH” or the “Company”) today announced a strategic transaction designed to sharpen its focus on next-generation controllable genetic medicines powered by its Regulator Dial™ technology platform (the “Retained Assets”) and unlock value for its Gene-Circuit-enabled pipeline, including SENTI-202, currently…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SNTI.
U.S. House Trading
No House trades found for SNTI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.